Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May

Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET

White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim® cochlear implant, a first-of-its-kind, fully implanted cochlear implant system. The Company will host a Fireside Chat with Dr. Theodore McRackan, MD, MSCR and Dr. Elizabeth Camposeo, AuD from the Medical University of South Carolina (MUSC) on Wednesday April 29, 2026 at 4:30 pm ET to review the data and its clinical implications.

A planned interim analysis of the clinical data for the first 10 patients was conducted following completion of their six-month follow-up visits. Initial safety and performance data were presented this past weekend by Dr. Camposeo at the American Academy of Audiology (AAA) Annual Conference and Dr. McRackan at the Combined Otolaryngology Spring Meetings (COSM). Additional podium presentations are scheduled for May including the American Cochlear Implant Alliance (ACIA) Conference on Friday, May 8, 2026, and the International Conference on Cochlear Implants and Other Implantable Technologies (CI2026) on Monday, May 11, 2026.